Targets › PSMA1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2029.
Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. (UniProt, P25786)
Open in Phaseline: the race on PSMA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lantheus Medical Imaging | [68Ga]-LNTH-2401 PSMA-targeting positron emission tomography (PET) imaging agent | PSMA1 | Phase 2 | Prostate Cancer | Sep 2029 |
Prostate Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.